Researchers show how damaged tissue is reshaped to trigger painful bone formation in muscles and tendons CHINA, ...

A new small molecule could treat and prevent excess bone formation. Fibrodysplasia ossificans progressiva (FOP) is an extremely rare disease estimated to affect about one in 2 million people worldwide ...

Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of heterotopic ossification in patients with FOP.

A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has developed a promising new therapeutic strategy for fibrodysplasia ossificans ...

Researchers uncover a redox-regulated mechanism that determines whether bone fractures heal or progress to non-union.

Bone regeneration research has taken a significant leap forward with the discovery of a crucial mechanism that could transform treatments for bone disorders. Scientists have identified how Discoidin ...

After serious injuries, burns, fractures, or major surgeries, the body normally repairs damaged tissues and restores movement ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...